Huntington's disease

Look out, Teva. Neurocrine's Ingrezza wins Huntington's disease FDA nod to rival Austedo
Look out, Teva. Neurocrine's Ingrezza wins Huntington's disease FDA nod to rival Austedo
Fierce Pharma
Neurocrine
Ingrezza
FDA
Huntington's disease
Teva Pharmaceutical
Flag link:
FDA Action Alert: Ipsen, Revance, Neurocrine and Regeneron
FDA Action Alert: Ipsen, Revance, Neurocrine and Regeneron
BioSpace
FDA
Ipsen
Revance Therapeutics
Neurocrine
Regeneron
palovarotene
fibrodysplasia ossificans progressiva
Daxxify
cervical dystonia
Ingrezza
chorea
Huntington's disease
pozelimab
CHAPLE disease
Flag link:
Companies to Watch: 12 Late-Stage Contenders in Neurodegenerative Disease
Companies to Watch: 12 Late-Stage Contenders in Neurodegenerative Disease
BioSpace
neurodegenerative disease
Alzheimer's disease
Axsome Therapeutics
Eli Lilly
Anavex
TauRx
AB Science
ALS
BrainStorm Cell Therapeutics
Seelos Therapeutics
Parkinson's Disease
AbbVie
Mitsubishi Tanabe Pharma
Annovis
Huntington's disease
Prilenia Therapeutics
Neurocrine
Flag link:
Uniqure’s accelerated approval hopes take a hit
Uniqure’s accelerated approval hopes take a hit
EP Vantage
uniQure
Huntington's disease
gene therapy
AMT-130
Flag link:
Teva gains FDA approval for once-daily formulation of flagship drug Austedo
Teva gains FDA approval for once-daily formulation of flagship drug Austedo
Fierce Pharma
Teva Pharmaceutical
FDA
Austedo
tardive dyskinesia
Huntington's disease
Flag link:
10 clinical trials to watch in the first half of 2023
10 clinical trials to watch in the first half of 2023
BioPharma Dive
clinical trials
Alzheimer's disease
obesity
Huntington's disease
M&A
AstraZeneca
Daiichi Sankyo
Nimbus Therapeutics
Takeda
Eli Lilly
Sanofi
Regeneron
Moderna Therapeutics
Gilead Sciences
Pfizer
Roivant
Alnylam
uniQure
Flag link:
Huntington's Disease Continues to Baffle Biopharma
Huntington's Disease Continues to Baffle Biopharma
BioSpace
Huntington's disease
Triplet Therapeutics
PTC Therapeutics
Flag link:
UniQure revs up engines again for Huntington's gene therapy after trial hospitalizations
UniQure revs up engines again for Huntington's gene therapy after trial hospitalizations
Fierce Biotech
uniQure
Huntington's disease
gene therapy
AMT-130
Flag link:
Teva reports data from Huntington’s disease-linked chorea trial
Teva reports data from Huntington’s disease-linked chorea trial
Clinical Trials Arena
Teva Pharmaceutical
Austedo
clinical trials
chorea
Huntington's disease
Flag link:
NeuBase Abandons Huntington's, 60% of Workforce in Strategic Pivot
NeuBase Abandons Huntington's, 60% of Workforce in Strategic Pivot
BioSpace
NeuBase
Huntington's disease
layoffs
Flag link:
Atlas-backed biotech focused on Huntington's disease shuts down less than three years after launch
Atlas-backed biotech focused on Huntington's disease shuts down less than three years after launch
Endpoints
Triplet Therapeutics
Huntington's disease
Flag link:
Safety worries spur Novartis to suspend drug dosing in Huntington’s trial
Safety worries spur Novartis to suspend drug dosing in Huntington’s trial
BioPharma Dive
Novartis
Huntington's disease
clinical trials
branaplam
Flag link:
BrainVectis gains approval for Phase I/II Huntington’s gene therapy trial
BrainVectis gains approval for Phase I/II Huntington’s gene therapy trial
Clinical Trials Arena
AskBio
BrainVectis
clinical trials
Huntington's disease
Flag link:
uniQure pauses part of Huntington's trial after 3 patients hospitalized—1 of whom hasn’t fully recovered
uniQure pauses part of Huntington's trial after 3 patients hospitalized—1 of whom hasn’t fully recovered
Fierce Biotech
uniQure
clinical trials
Huntington's disease
AMT-130
Flag link:
uniQure shares spike as investors see bright spot in 12-month Huntington's gene therapy data
uniQure shares spike as investors see bright spot in 12-month Huntington's gene therapy data
Fierce Biotech
uniQure
Huntington's disease
gene therapy
AMT-130
Flag link:
bit.bio’s New Huntington’s Disease Human Cell Model Set to Accelerate Drug Discovery and Screening
bit.bio’s New Huntington’s Disease Human Cell Model Set to Accelerate Drug Discovery and Screening
BioSpace
bit.bio
Huntington's disease
ioDisease Model
drug discovery
Flag link:
Roche sees cause for optimism with failed Huntington's disease drug. Others aren't so sure.
Roche sees cause for optimism with failed Huntington's disease drug. Others aren't so sure.
BioPharma Dive
Roche
clinical trials
Huntington's disease
Flag link:
Rewind: Roche returns to phase 2 after seeing post hoc signal in failed pivotal Huntington's trial
Rewind: Roche returns to phase 2 after seeing post hoc signal in failed pivotal Huntington's trial
Fierce Biotech
Roche
Ionis Pharmaceuticals
tominersen
Huntington's disease
clinical trials
Flag link:
Annexon becomes the latest group to provide a confusing update in Huntington's disease
Annexon becomes the latest group to provide a confusing update in Huntington's disease
EP Vantage
Annexon Biosciences
Huntington's disease
clinical trials
ANX005
Flag link:
A high-profile gene therapy biotech takes aim at Huntington's
A high-profile gene therapy biotech takes aim at Huntington's
BioPharma Dive
Passage Bio
gene therapy
Huntington's disease
Flag link:

Pages